Ischaemic heart disease may pred ispose to pseudophakic cystoid macular oedema
Abstract
Purpose Pseudophakic macular oedema (PMO) is uncommon following uncomplicated phacoemulsification and lens implantation and the cause of infrequent cases is rarely understood. This study was undertaken to determine whether a relationship exists between ischaemic heart disease (IHD) and PMO. Methods Retrospective case note review was carried out of 177 (252 eyes) consecutive patients without pre-existing retinal disease who underwent phacoemulsification and intraocular lens implantation during a 12 month period. Patients with a post-operative best corrected visual acuity < 6/9 underwent slit-lamp biomicroscopy and fluorescein angiography to identify PMO. IHD was defined on clinical and electrocardiographic grounds. The incidence of IHD was compared in patients with and without PMO and statistical analysis performed using the Fisher's exact test. Results PMO occurred in 4 patients (6 eyes), all of whom had IHD, whereas no PMO occurred in the remaining 173 patients (246 eyes) (p = 0.04). Conclusions Pseudophakic macular oedema represents an important complication following modem phacoemulsification and intraocular lens implantation and is associated significantly with ischaemic heart disease. Ischaemic heart disease (IHD) was defined as:
(i) evidence of ischaemic damage on the p re operative electrocardiogram (ECG), as determined by a consultant cardiologist masked to the ophthalmic diagnosis, (ii) a clinical history of IHD and (iii) both. In all cases, the operative procedure was planned sutureless phacoemulsification with a 3.2 mm clear corneal pocket incision. All patients had a Chiron C11 UB injectable silicone lens implant. Post-operative review occurred on the day of surgery and at 3 weeks. Patients with best corrected visual acuity < 6/9 were examined as above for evidence of PMO with additional follow-up visits as appropriate.
The incidence of PMO was compared in patients with and without IHD and statistical analysis performed using the Fisher's exact test.
Results
Retrospective analysis of 290 casenotes excluded 113 patients from our cohort due to either operative complications or coexisting disease. The latter included (i) diabetic retinopathy (n = 51), (ii) age-related macular degeneration (n= 33), (iii) dense trachoma (n = 7), (iv) significant myopic degeneration (n = 6), (v) amblyopia in the operated eye (n = 3), (vi) full-thickness macular holes (n = 2), (vii) previous macula-off retinal detachment (n = 1), (viii) benign intracranial hypertension (n = 1). Patients with operative complications included 8 of 290 in the IHD patients without PMO (n = 80) revealed VA > 6/5 in 36,6/6-6/9 in 38 and < 6/9 in 6. In patients with no evidence of IHD (n = 93) VA was> 6/5 in 34, 6/6-6/9 in 50 and < 6/9 in 9. In both groups all those with VA < 6/9 (n = 15) were examined and the VA accounted for by reasons other than PMO, including age-related macular degeneration (10 cases), optic neuropathy (2 cases) and post-operative anterior uveitis (3 cases). Four patients (6 eyes) developed PMO, all of whom had evidence of IHD ( Table 1 ). The ECG evidence was confirmed in all cases by a consultant cardiologist masked to any information regarding history, medications and ophthalmic diagnosis ( Table 2 ). The macular oedema was diagnosed in each case at the 3 week post-operative visit (Fig. 1a) 
(a)
from the perifoveal capillaries in the transient phase followed by petaloid macular leakage and disc hyperfluorescence in the late frames (Fig. lb, c) . Statistical analysis comparing the incidence of PMO in patients with and without IHD revealed an association between IHD and PMO (p < 0.04).
Discussion
This study suggests a relationship between pseudophakic macular oedema (PMO) and ischaemic heart disease (IHD), 4 patients with IHD developing PMO compared with no unaffected patients (p < 0.04). That 2 of the cases were bilateral and cases with coexisting retinal disease or complicated surgery were excluded, makes a chance association unlikely. The timing, moderate reduction in visual acuity, clinical and angiographic features and outcome were all consistent with classic PMO.
Our patient cohort consisted of all cataract operations taking place at a district general hospital (Ealing) under the care of one consultant O.D.s.) during a 1 year period There were no tertiary referrals and all patients were placed without prioritisation on a routine local anaesthetic waiting list.
The exact pathogenesis of PMO remains unclear, and may be multifactorial. Factors likely to be important include post-operative inflammation with a concomitant disturbance in the blood-aqueous barrier, vitreomacular traction and changes in the fluid dynamics in the retinal Inflammation in PMO is believed to result from breakdown of the blood-aqueous barrier, which presumably becomes compromised secondary to direct iris trauma, altered aqueous fluid dynamics over the surface of the iris, or a combination of these. Vitreomacular traction has been implicated in the pathogenesis of PM0 25 because unilateral cases in which vitreous loss or vitreous wick syndrome is present make up over 50% of unilateral cases and there is frequently a good response to lysis of the vitreous wick. Histological evidence shows vitreous traction producing cystic retinal spaces and macular holes in some PMO cases.
PMO ultimately occurs as a result of distortion in the perifoveal capillary network disturbance leading to fluid accumulation largely in the outer plexiform layer. The likelihood of developing PMO depends on the dynamics of forces acting on perifoveal capillaries and the competency of the blood-retinal barrier. Oedema will occur if fluid filtration exceeds the rate of removal from the extracellular space. Increased filtration is favoured by high precapillary hydrostatic pressure and breakdown of the blood-retinal barrier, and removal reduced if plasma protein levels are low or retinal tissue compliance which is typically high is reduced. Although retinal autoregulation prevents an increase in capillary blood flow, there is evidence of impairment in hypertension and diabetes and this perhaps explains the increased incidence of PMO in these disorders. Thirty-six of 48 patients in one study l of PMO had evidence of systemic hypertension and 4 others had cardiovascular disease. Whilst there is an increased incidence of IHD in patients with hypertension, it may be that autoregulation is impaired in IHD due to a failure of the precapillary arteriole to respond to autoregulatory signals. However, there is no direct evidence for this of which we are aware.
In addition patients with IHD do not have significantly low serum total protein levels or recognised abnormalities of the blood-ocular barrier or even b lood-brain barrier that might predispose them to PMO. ln summary, whilst capillary fragility, in both the iris and retina, may be increased in patients with IHD predisposing to breakdown of the blood-aqueous barrier and blood-retinal barriers, direct evidence is lacking.
This study has implications for the prophylaxis and management of PMO. We do not routinely use NSAIDs to prevent PMO. Whilst there is good evidence that they are effective both as prophylactic agents and in the treatment of established cases, 26 and that they reduce the degree and duration of blood-aqueous barrier breakdown, the incidence of clinically significant PMO after uncomplicated phacoemulsification and lens implantation, is so low « 2.5% in this study) that routine prophylaxis seems hard to justify. However, we would now recommend their prophylactic use in patients with pre-existing hypertension or cardiovascular disease including IHD. In addition they are indicated in any patient undergoing second eye cataract surgery in whom the first eye developed PMO after surgery. Furthermore, we would recommend their post-operative use to treat any patient who develops PMO, of whatever cause, in the first few weeks after surgery.
